Sexual & Hormonal Health
Peptides for Fertility: Egg & Sperm Evidence Ranked (2026)
The honest fertility-peptide record: the strongest evidence belongs to the prescription reproductive hormones already in every IVF clinic — hCG, gonadotropins, gonadorelin — plus one investigational frontier, kisspeptin. No over-the-counter research peptide has human fertility data.
hCGGonadotropins (FSH/LH)GonadorelinKisspeptinIVF triggerMale fertility
The quick verdict
The honest ranking: the strongest fertility peptides are the FDA-approved reproductive hormones already in every IVF clinic — hCG, gonadotropins, pulsatile gonadorelin — with kisspeptin as the one investigational frontier and no over-the-counter research peptide carrying any human fertility data.
- Best overall
- hCG (human chorionic gonadotropin) — The anchor fertility peptide — FDA-approved for ovulation triggering and male hypogonadism, RCT and large-cohort backed, and the LH-replacement backbone of male-factor fertility care.
- Best value
- Gonadotropins (FSH & LH) — The meta-analysis-backed workhorse of ovulation induction and IVF for women and FSH replacement for male spermatogenesis — decades-old, FDA-approved core pharmacology for both sexes.
- Best for High-OHSS-risk IVF trigger (investigational)
- Kisspeptin-54 — Phase 2 data show a 45% live-birth rate with zero moderate or severe OHSS — a real safety edge over hCG triggers — but it remains unapproved and pre-Phase-3.
How we evaluated
We ranked candidate fertility peptides strictly by the strength of human evidence for egg and sperm endpoints — randomized controlled trials and meta-analyses first, then cohort and observational data, then mechanistic or preclinical signals — and we separate FDA-approved therapies from investigational and grey-market uses. This is informational, evidence-first editorial content, not medical advice and not a sourcing guide; the most evidence-based fertility peptides are prescription hormones used under specialist supervision.
- Human fertility-outcome evidence. Highest weight to live-birth, pregnancy, oocyte-maturation and spermatogenesis endpoints from RCTs, meta-analyses and large cohorts — not surrogate biomarkers or animal data.
- Regulatory & approval status. FDA-approved indications rank above investigational or compounded uses; grey-market or non-pulsatile misuse is flagged and downgraded.
- Condition-specific safety. OHSS and multiple-pregnancy risk in women, estradiol/gynecomastia and axis effects in men, and the need for monitored specialist delivery.
- Honesty about gaps. Where evidence is mechanistic, observational, or preclinical only, the peptide is graded and ranked accordingly — preclinical promise never earns an A or B.
Rating scale: 1-5 stars, weighted toward human fertility-outcome evidence and regulatory status; evidence grade (A-D, or X for honest preliminary) shown per item.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | hCG (human chorionic gonadotropin) | A | 5.0 | Ovulation/oocyte-maturation triggering in women and LH-replacement spermatogenesis in men with hypogonadotropic hypogonadism or post-TRT axis suppression | Prescription; varies by pharmacy |
| 2 | Gonadotropins — FSH & LH (recombinant and urinary/menopausal) | A | 5.0 | Controlled ovarian stimulation for IVF/ICSI in women and FSH replacement (with hCG) for male spermatogenesis | Prescription; varies by pharmacy |
| 3 | Gonadorelin (synthetic GnRH, pulsatile) | B | 4.0 | Hypothalamic-origin infertility — congenital hypogonadotropic hypogonadism in men and hypothalamic amenorrhea in women | Specialist/compounded; varies |
| 4 | Kisspeptin (KP-54 / KP-10) | B | 3.5 | Investigational IVF trigger for high-OHSS-risk women (research/monitored settings); a male-fertility biomarker, not a treatment | Investigational; not commercially available |
| 5 | Research-chemical peptides (BPC-157, TB-500, GHK-Cu, epitalon, MOTS-c) | D | 1.0 | Nothing, for fertility — listed only to document what the evidence does NOT support | Sold as research chemicals; unregulated |
hCG (human chorionic gonadotropin)
The FDA-approved anchor peptide of fertility medicine, for both sexes
hCG is the most-established peptide hormone in all of fertility medicine, with FDA-approved indications on both the female and male side. It is a placental glycoprotein that activates the LH receptor; pharmaceutical hCG is urinary-derived (Pregnyl, Novarel) or recombinant (choriogonadotropin alfa, Ovidrel). In women it is the standard ovulation and oocyte-maturation trigger that completes final follicular maturation before egg retrieval or timed intercourse and IUI: in a large retrospective cohort of 5,610 first natural-cycle donor-sperm IUI cycles, an hCG-triggered group had significantly higher clinical pregnancy (27.4% vs 22.7%) and live-birth (24.5% vs 20.1%) rates than spontaneous-LH-surge cycles. In men with hypogonadotropic hypogonadism, hCG provides LH replacement that induces spermatogenesis in the majority of patients — combined hCG plus FSH achieves complete spermatogenesis in roughly 70-90%. Its single most important men's-fertility role is reversing testosterone-induced infertility: TRT is a contraceptive, and hCG is part of how clinicians restart the suppressed axis. The defining caveat is OHSS in women, which hCG triggering is the major driver of.
Strengths
- FDA-approved for both ovulation triggering and male hypogonadism
- Backed by RCT and large-cohort human data on live birth and spermatogenesis
- The LH-replacement backbone that can restore sperm after TRT/anabolic suppression
Weaknesses
- In women, the major driver of ovarian hyperstimulation syndrome (OHSS)
- In men can raise estradiol (gynecomastia) and is monotherapy-limited when FSH activity is also needed
- Prohibited in males at all times under WADA (S2.2.1)
- Best for
- Ovulation/oocyte-maturation triggering in women and LH-replacement spermatogenesis in men with hypogonadotropic hypogonadism or post-TRT axis suppression
- Pricing
- Prescription; varies by pharmacy
Source: Maquiling et al., Front Endocrinol 2020 (5,610-cycle cohort)
Gonadotropins — FSH & LH (recombinant and urinary/menopausal)
The meta-analysis-backed workhorse of ovulation induction and IVF
Gonadotropins are the actual pituitary output hormones, given as recombinant FSH (follitropin alfa/beta), recombinant LH (lutropin alfa), or urinary human menopausal gonadotropin (hMG, which contains FSH plus LH activity) — marketed as Gonal-f, Follistim, and Menopur among others. In women they are standard care for controlled ovarian stimulation in IVF and ICSI, recruiting multiple follicles; multiple RCTs and meta-analyses establish their efficacy, and one meta-analysis found hMG associated with a roughly 4% higher live-birth rate than recombinant FSH after long GnRH-agonist down-regulation, while recombinant FSH tends to yield more oocytes per dose. LH supplementation benefits specific subgroups such as poor responders. In men, FSH (typically added to hCG) drives Sertoli-cell function and is required to induce and maintain spermatogenesis in many men with hypogonadotropic hypogonadism, supported by pubertal-induction and fertility meta-analyses. These are not self-administered hacking compounds: female stimulation cycles require ultrasound and estradiol monitoring, and the principal risks are OHSS and multiple pregnancy. Alongside hCG, gonadotropins form the FDA-approved, meta-analysis-backed core of fertility pharmacology for both sexes.
Strengths
- FDA-approved and established by multiple RCTs and meta-analyses for IVF/ovulation induction
- Cover both female follicle recruitment (FSH) and male spermatogenesis (FSH with hCG)
- Flexible formulations (recombinant FSH, recombinant LH, urinary hMG) tailored to subgroup needs
Weaknesses
- OHSS and multiple pregnancy are the principal female risks, mandating cycle monitoring
- Require specialist administration and monitoring — not lifestyle injectables
- Cost and daily injection burden across an 8-12 day stimulation cycle
- Best for
- Controlled ovarian stimulation for IVF/ICSI in women and FSH replacement (with hCG) for male spermatogenesis
- Pricing
- Prescription; varies by pharmacy
Source: DARE/NCBI systematic review — hMG vs rFSH (NBK75153)
Gonadorelin (synthetic GnRH, pulsatile)
Pump-delivered pulsatile GnRH — the physiologic restart for hypothalamic infertility
Gonadorelin is identical to endogenous GnRH; delivered in pulses by a portable pump, it makes the patient's own pituitary secrete LH and FSH, the most physiological way to restart a hypothalamic-origin reproductive axis. In men with congenital hypogonadotropic hypogonadism, a pulsatile GnRH pump induces spermatogenesis effectively — a meta-analysis pooling roughly 420 men across 8 studies found pulsatile GnRH achieved earlier spermatogenesis onset than combined gonadotropin therapy, and in men who had previously failed combined hCG/hMG, switching to pulsatile GnRH produced sperm in 17 of 28 (60.7%). In women, historic pulsatile GnRH (Lutrepulse) was used to induce ovulation in hypothalamic GnRH deficiency, a recognized physiologic method now niche given gonadotropin availability. As Factrel, gonadorelin is FDA-approved for the GnRH stimulation test, but no FDA-approved gonadorelin fertility/pump product is actively marketed in the U.S.; pulsatile fertility use runs through specialty/compounded supply and is more established in Europe and China. Critically, this validated pump protocol is not the single-injection, non-pulsatile grey-market gonadorelin sold online for TRT, which has no fertility-outcome evidence. Because it relies on an intact pituitary, it fails when the defect is pituitary or gonadal.
Strengths
- Solid human cohort and meta-analytic evidence in hypothalamic-origin infertility
- Most physiological approach — the body's own pituitary produces LH and FSH
- Meta-analysis shows earlier spermatogenesis than combined gonadotropins in CHH men
Weaknesses
- Requires a continuously worn pump with infusion-site burden and titration
- Fails when the defect is pituitary or gonadal rather than hypothalamic
- No actively marketed U.S. fertility/pump product; not the online single-shot 'gonadorelin'
- Best for
- Hypothalamic-origin infertility — congenital hypogonadotropic hypogonadism in men and hypothalamic amenorrhea in women
- Pricing
- Specialist/compounded; varies
Source: Zhang et al., Am J Mens Health 2019 (pulsatile GnRH vs gonadotropins)
Kisspeptin (KP-54 / KP-10)
The investigational IVF trigger that may eliminate severe OHSS — still unapproved
Kisspeptin is the most promising novel fertility peptide and the one with genuinely interesting human data. It acts one step above GnRH, inducing an LH surge that depends on the patient's own endogenous GnRH reserve, producing a shorter, more physiological surge than hCG. As an IVF trigger in women the evidence is Grade B (surrogate and early-outcome RCTs): kisspeptin-54 first triggered egg maturation in a first-in-human trial, and in a Phase 2 study of 60 high-OHSS-risk women it triggered oocyte maturation in 95% (57/60), with clinical pregnancy 53% and live birth 45% per transfer — and critically no moderate, severe, or critical OHSS and no kisspeptin-related adverse events. A dose-optimization RCT showed a second dose at 10 hours further improved maturation. In men the data are only Grade C for treatment: KP-10 reliably raises LH and testosterone and serum kisspeptin correlates with sperm concentration as a possible biomarker, but no controlled trial shows kisspeptin treats male infertility. The honest gaps are large — no completed Phase 3, KP-10's roughly 4-minute half-life, research-only IV/SC delivery — and it is legally a dead end for self-use: not FDA-approved, the FDA's PCAC recommended against adding kisspeptin-10 to the 503A compounding list, and it is WADA-prohibited in males.
Strengths
- Best novel-peptide human fertility data — Phase 2 RCTs with real outcomes
- OHSS-sparing: zero moderate/severe OHSS in high-risk women, a genuine safety advance
- Strikingly well tolerated with no kisspeptin-attributable adverse events in IVF trials
Weaknesses
- Investigational — no completed Phase 3 IVF-trigger trial and not FDA-approved
- KP-10 half-life is about 4 minutes; delivered IV/SC in research settings only
- FDA PCAC recommended against 503A compounding; prohibited in males under WADA — no legal self-use path
- Best for
- Investigational IVF trigger for high-OHSS-risk women (research/monitored settings); a male-fertility biomarker, not a treatment
- Pricing
- Investigational; not commercially available
Source: Abbara et al., J Clin Endocrinol Metab 2015 (Phase 2 RCT, n=60)
Research-chemical peptides (BPC-157, TB-500, GHK-Cu, epitalon, MOTS-c)
Popular biohacker peptides with zero human fertility evidence
This entry exists to set expectations honestly: there is no over-the-counter research peptide with human evidence for treating infertility. BPC-157, TB-500 (thymosin beta-4), GHK-Cu, epitalon, MOTS-c, and the bioregulator and longevity peptides have no human fertility-outcome trials whatsoever. Claims that they improve egg quality or boost sperm are extrapolation from mechanism or animal work, or outright marketing, and grade C to D at best for fertility. If a fertility peptide stack sold online includes any of these, it is unproven for that purpose. These compounds are also, in several cases, not FDA-approved and sold as research chemicals not for human use, carrying product-purity hazards. From a root-cause, functional-medicine lens, the highest-yield move before any injectable is diagnostic — identifying why ovulation or spermatogenesis is failing (thyroid, insulin resistance/PCOS, hypothalamic suppression from undereating or overtraining, hyperprolactinemia, varicocele, toxicant load, or exogenous testosterone use) and correcting that. We include this group not as a recommendation but as a warning: they are the peptides most heavily marketed for fertility and the least supported by evidence.
Strengths
- Widely available and inexpensive relative to prescription hormones (their only practical 'advantages')
- Some have coherent preclinical mechanisms in unrelated tissue-repair contexts
- Transparency here helps readers avoid diverting from an actual diagnostic work-up
Weaknesses
- Zero human fertility-outcome trials — no evidence they improve egg or sperm outcomes
- Often unapproved research chemicals with endotoxin, heavy-metal and dosing-accuracy hazards
- Marketing these for fertility diverts time and money from evidence-based evaluation
- Best for
- Nothing, for fertility — listed only to document what the evidence does NOT support
- Pricing
- Sold as research chemicals; unregulated
Source: Trevisan et al., J Clin Med 2025 (kisspeptin/fertility peptide review)
Frequently asked
What is the single best-evidenced peptide for fertility?
There is no contest: human chorionic gonadotropin (hCG) and the gonadotropins (FSH and LH). These are FDA-approved and backed by randomized controlled trials and meta-analyses for ovulation triggering, IVF stimulation, and male spermatogenesis. They simply are not marketed as biohacker peptides, but pharmacologically that is exactly what they are — peptide and glycoprotein hormones that replace the precise signals driving egg and sperm production. Everything ranked below them has weaker human evidence, and no over-the-counter research peptide has any fertility-outcome data at all.
Is kisspeptin a safer way to trigger IVF than hCG?
The Phase 2 evidence is genuinely encouraging. Kisspeptin-54 triggered oocyte maturation with a 45% live-birth rate per transfer and, critically, zero moderate, severe, or critical OHSS in high-risk women, because it produces a shorter, self-limited LH surge that relies on the patient's own GnRH reserve. That OHSS-sparing profile is its reason for being. But kisspeptin remains investigational — no completed Phase 3, not FDA-approved, and the FDA's advisory committee recommended against adding kisspeptin-10 to the 503A compounding list. It is scientifically the frontier but clinically still pre-approval, so it is not yet standard care.
Can a man on testosterone (TRT) just add a peptide to stay fertile?
The relevant peptide is hCG, sometimes with FSH or pulsatile GnRH, used to maintain or restore spermatogenesis. But the core problem is the testosterone itself: exogenous testosterone and anabolic steroids suppress the hypothalamic-pituitary-gonadal axis and shut down sperm production, so TRT effectively acts as a contraceptive. Retrospective real-world data show hCG can restore spermatogenesis in men whose production was suppressed by non-prescribed androgens. The evidence-based path usually involves stopping or modifying testosterone under a specialist and restarting the axis with hCG, with or without FSH, under monitoring — not adding a vial while continuing TRT.
Do BPC-157 or other research peptides improve egg or sperm quality?
No. There are no human fertility-outcome trials for BPC-157, TB-500, GHK-Cu, epitalon, MOTS-c, or similar bioregulator and longevity peptides. Claims that they improve egg quality or boost sperm are extrapolation from mechanism or animal data, or marketing, and grade C to D at best for fertility. If a fertility stack includes these, it is unproven for that purpose. The highest-yield step before any injectable is diagnostic — identifying why ovulation or spermatogenesis is failing, because these signals work only when the downstream gametes and the rest of the axis are viable.
Is gonadorelin a good fertility option?
For the specific situation of hypothalamic-origin infertility — congenital hypogonadotropic hypogonadism in men or hypothalamic amenorrhea in women — pulsatile gonadorelin has Grade B human evidence, including a meta-analysis of roughly 420 men showing earlier spermatogenesis than combined gonadotropins, and a cohort where 17 of 28 men who had failed gonadotropins produced sperm after switching to pulsatile GnRH. It requires a portable pump delivering a pulse roughly every 90 minutes and is a niche specialist therapy. It is not the single-shot gonadorelin sold online for TRT, which is non-pulsatile and has no fertility-outcome evidence.
Can these peptides fix age-related egg quality or azoospermia from testicular failure?
No. hCG, FSH, LH, gonadorelin, and kisspeptin all replace hormonal signals — they do not create gametes. They work only when the downstream machinery is intact and the block is hormonal: an intact ovarian reserve, or testicular tissue still capable of producing sperm. They cannot reverse age-related decline in egg quality, primary ovarian insufficiency, or non-obstructive azoospermia from primary testicular failure. Chasing these hormones without a diagnosis wastes time on the biological clock, which is why a full work-up by a reproductive endocrinologist or urologist comes first, before any injectable.